Free Trial
NASDAQ:KTTA

Pasithea Therapeutics 5/14/2024 Earnings Report

Pasithea Therapeutics logo
$0.73 +0.01 (+1.86%)
Closing price 09/19/2025 04:00 PM Eastern
Extended Trading
$0.72 -0.02 (-2.20%)
As of 09/19/2025 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pasithea Therapeutics EPS Results

Actual EPS
-$3.70
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Pasithea Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pasithea Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Pasithea Therapeutics' next earnings date is estimated for Wednesday, November 12, 2025, based on past reporting schedules.

Conference Call Resources

Pasithea Therapeutics Earnings Headlines

Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
See More Pasithea Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pasithea Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pasithea Therapeutics and other key companies, straight to your email.

About Pasithea Therapeutics

Pasithea Therapeutics (NASDAQ:KTTA), Inc. (NASDAQ: KTTA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and eventual commercialization of engineered antibody therapeutics for immunological diseases. Leveraging a proprietary discovery engine that integrates advanced computational biology, high-throughput screening and structural analysis, the company aims to identify and generate novel therapeutic molecules that modulate key immune pathways.

The company’s pipeline consists of multiple preclinical and early clinical candidates targeting autoimmune and inflammatory disorders. Pasithea’s research approach centers on human-derived antibodies with tailored specificity and functionality, addressing areas of high unmet need such as severe chronic inflammatory conditions. By applying its platform to a range of targets, Pasithea seeks to advance innovative therapies toward regulatory milestones and strategic partnerships.

Headquartered in Seattle, Washington, Pasithea Therapeutics maintains research and development operations in the Pacific Northwest, with teams dedicated to antibody engineering, translational science and regulatory strategy. The company is led by a management team with experience in biotechnology innovation, clinical development and commercialization, supported by a board of directors and scientific advisors drawn from leading academic and industry institutions. Pasithea continues to explore collaborations with academic centers and pharmaceutical partners to accelerate its therapeutic programs.

View Pasithea Therapeutics Profile

More Earnings Resources from MarketBeat